Association of major cardiovascular risk factors with the development of acute coronary syndrome in Lithuania [0.03%]
立陶宛急性冠脉综合征患者主要心血管危险因素分析
Indrė Čeponienė,Diana Žaliaduonytė-Pekšienė,Olivija Gustienė et al.
Indrė Čeponienė et al.
Cardiovascular (CV) disease remains the leading cause of death in Lithuania. Timely recognition of CV risk factors and intervention to reduce these risk factors is of absolute importance to prevent coronary heart disease and reduce its burd...
Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan [0.03%]
心血管-肾脏综合征的药理学方法：左西孟丹的作用
Francesco Fedele,Kristjan Karason,Simon Matskeplishvili
Francesco Fedele
Pathological interplay between the heart and kidneys-also known as cardio-renal syndrome (CRS)-is frequently encountered in heart failure and is linked to worse prognosis and quality of life. Drug therapies for this complex situation may in...
The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure [0.03%]
乐西美坦作为心力衰竭疾病修正疗法以维持患者生存质量的潜在价值
Markku S Nieminen,Cândida Fonseca,Dulce Brito et al.
Markku S Nieminen et al.
Maintaining adequate quality of life (QoL) is an important therapeutic objective for patients with advanced heart failure and, for some patients, may take precedence over prolonging life. Achieving good QoL in this context may involve aspec...
The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure [0.03%]
左西孟丹重复剂量治疗终末期心力衰竭
Juan F Delgado,Fabrizio Oliva,Alexander Reinecke
Juan F Delgado
Inotropes may be an appropriate response for some patients with advanced heart failure who remain highly symptomatic despite optimization of evidence-based therapy. These patients need to be supported waiting for a heart transplant or ventr...
The inodilator levosimendan as a treatment for acute heart failure in various settings [0.03%]
莱vosimendan治疗各种环境下急性心力衰竭的效果
Finn Gustafsson,Fabio Guarracino,Robert H G Schwinger
Finn Gustafsson
Levosimendan is an inodilator developed for treatment of acute heart failure. It was shown to enhance cardiac contractility, and to exert a vasodilatory effect in all vascular beds. In some trials, the use of levosimendan was associated wit...
ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary [0.03%]
意大利ANMCO/AIOM/AICO心脏肿瘤临床路径和管理指南共识文件执行总结
Luigi Tarantini,Michele Massimo Gulizia,Andrea Di Lenarda et al.
Luigi Tarantini et al.
Cardiovascular disease and cancer are leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced s...
ANMCO/SIC/SICI-GISE/SICCH Executive Summary of Consensus Document on Risk Stratification in elderly patients with aortic stenosis before surgery or transcatheter aortic valve replacement [0.03%]
老年主动脉瓣狭窄患者手术或经导管主动脉瓣植入术前风险分层专家共识执行摘要
Giovanni Pulignano,Michele Massimo Gulizia,Samuele Baldasseroni et al.
Giovanni Pulignano et al.
Aortic stenosis is one of the most frequent valvular diseases in developed countries, and its impact on public health resources and assistance is increasing. A substantial proportion of elderly people with severe aortic stenosis is not elig...
ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training [0.03%]
非瓣膜性房颤患者左心耳封堵的ANMCO/AIAC/SICI-GISE/SIC/SICCH共识文件：指征、患者选择、人员技能、组织和培训
Gavino Casu,Michele Massimo Gulizia,Giulio Molon et al.
Gavino Casu et al.
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence is increasing due to the progressive aging of the population. About 20% of strokes are attributable to AF and AF patients are at five-fold increased risk of stroke. T...
ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism [0.03%]
意大利心脏病学学会关于肺血栓栓塞症患者长期随访的立场文件
Carlo D&#x;Agostino,Pietro Zonzin,Iolanda Enea et al.
Carlo D&#x;Agostino et al.
Venous thromboembolism (VTE), including pulmonary embolism and deep venous thrombosis, is the third most common cause of cardiovascular death. The management of the acute phase of VTE has already been described in several guidelines. Howeve...